Home › Cancro al seno › California › Orange
Studi clinici su Cancro al seno a Orange, CA
14 studi su Cancro al seno cercano partecipanti presso sedi a Orange e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
In reclutamentoFase 3
- UC Irvine Medical Center, Orange
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
In reclutamentoFase 1/2
- University of California Irvine, Orange
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
In reclutamentoFase 2
- Community Clinical Trials, Orange
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
In reclutamentoFase 2
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
In reclutamentoFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
In reclutamentoFase 3
- UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
In reclutamentoFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
E-Mindfulness Approaches for Living After Breast Cancer
In reclutamentoFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
In reclutamentoFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
In reclutamentoFase 1/2
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
In reclutamentoFase 3
- Saint Joseph Hospital - Orange, Orange
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
In reclutamentoFase 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
In reclutamentoFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Orange
Studi su Cancro al seno in altre città
- New York City, NY134 studi
- Houston, TX126 studi
- Boston, MA111 studi
- Nashville, TN80 studi
- Los Angeles, CA72 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Durham, NC63 studi
- Queens, NY63 studi
- Chicago, IL58 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Altri studi a Orange
- Cancro del polmone non a piccole cellule25 studi
- Cancro metastatico20 studi
- Cancro colorettale16 studi
- Cancro ovarico16 studi
- Cancro pancreatico15 studi
- Cancro ai polmoni14 studi
- Cancro alla prostata14 studi
- Cancro al fegato (carcinoma epatocellulare)14 studi
- Melanoma14 studi
- Leucemia mieloide acuta13 studi
- Cancro (tutti i tipi)13 studi
- Cancro dello stomaco13 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.